Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Discover the 7 warning signs of ulcerative colitis, plus breakthrough treatments and management strategies that can transform ...

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as ...

The human gut is home to trillions of bacteria that play vital roles in digestion, immunity, and overall health. When this ...

Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in combination with current ...

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...